Faron Pharmaceuticals Oy Change of Broker
11 Février 2025 - 8:30AM
RNS Regulatory News
RNS Number : 6628W
Faron Pharmaceuticals Oy
11 February 2025
Faron Pharmaceuticals
Ltd.
("Faron"
or "the Company")
Change of
Broker
Company announcement, 11 February
2025
TURKU, FINLAND -
Faron Pharmaceuticals Ltd. (AIM: FARN, First
North: FARON), a clinical-stage biopharmaceutical company focused
on tackling cancers via novel immunotherapies, announces the
appointment of Cairn Financial Advisers LLP as broker to the
Company with immediate effect in place of Peel Hunt LLP.
Cairn Financial Advisers LLP will also continue to act as the
Company's Nominated Adviser.
For
more information please contact:
ICR Healthcare
Mary-Jane Elliott, David Daley, Lindsey
Neville
Phone: +44 (0)20 3709 5700
E-mail: faron@icrhealthcare.com
Cairn Financial Advisers LLP,
Nominated Adviser and Broker
Sandy Jamieson, Jo Turner
Phone: +44 (0) 207 213
0880
Sisu Partners Oy, Certified Adviser
on Nasdaq First North
Juha Karttunen
Phone: +358 (0)40 555
4727
Jukka Järvelä
Phone: +358 (0)50 553
8990
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
APPPKDBKOBKKKBD
Faron Pharmaceuticals Oy (LSE:FARN)
Graphique Historique de l'Action
De Fév 2025 à Mar 2025
Faron Pharmaceuticals Oy (LSE:FARN)
Graphique Historique de l'Action
De Mar 2024 à Mar 2025
